Lion Biotechnologies Inc. (NASDAQ:LBIO) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday.

According to Zacks, “Lion Biotechnologies, Inc. is developing autologous cell therapies for the treatment of cancer. The Company’s lead product candidate, C?ntego(TM), is an autologous cell therapy indicated for the treatment of metastatic melanoma. Lion Biotechnologies, Inc., formerly known as Genesis Biopharma, Inc., is based in Woodland Hills, California. “

Several other equities analysts have also recently issued reports on LBIO. Roth Capital reissued a “buy” rating and issued a $15.00 price objective on shares of Lion Biotechnologies in a research note on Friday, August 26th. Jefferies Group reissued a “buy” rating and issued a $13.00 price objective on shares of Lion Biotechnologies in a research note on Monday. Chardan Capital set a $20.00 price objective on shares of Lion Biotechnologies and gave the company a “buy” rating in a research note on Sunday, August 21st. Finally, Cowen and Company reissued a “buy” rating on shares of Lion Biotechnologies in a research note on Friday, November 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $18.29.

Analyst Recommendations for Lion Biotechnologies (NASDAQ:LBIO)

Shares of Lion Biotechnologies (NASDAQ:LBIO) opened at 7.55 on Wednesday. The stock has a 50 day moving average of $6.95 and a 200-day moving average of $7.43. Lion Biotechnologies has a 12 month low of $4.24 and a 12 month high of $9.58. The firm’s market capitalization is $441.19 million.

In other Lion Biotechnologies news, Director Sanford Hillsberg sold 54,000 shares of the business’s stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $9.11, for a total transaction of $491,940.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 11.80% of the company’s stock.

Several large investors have recently modified their holdings of LBIO. FMR LLC raised its stake in shares of Lion Biotechnologies by 1.9% in the second quarter. FMR LLC now owns 5,645,114 shares of the biotechnology company’s stock valued at $45,725,000 after buying an additional 102,886 shares during the last quarter. Franklin Resources Inc. raised its stake in Lion Biotechnologies by 55.6% in the second quarter. Franklin Resources Inc. now owns 3,388,500 shares of the biotechnology company’s stock valued at $26,467,000 after buying an additional 1,210,500 shares in the last quarter. Alliancebernstein L.P. raised its stake in Lion Biotechnologies by 253.6% in the second quarter. Alliancebernstein L.P. now owns 39,600 shares of the biotechnology company’s stock valued at $321,000 after buying an additional 28,400 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in Lion Biotechnologies by 1.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 1,141,201 shares of the biotechnology company’s stock valued at $9,244,000 after buying an additional 14,415 shares in the last quarter. Finally, BlackRock Fund Advisors raised its stake in Lion Biotechnologies by 1.3% in the second quarter. BlackRock Fund Advisors now owns 1,807,203 shares of the biotechnology company’s stock valued at $14,638,000 after buying an additional 22,544 shares in the last quarter. Institutional investors own 71.30% of the company’s stock.

Lion Biotechnologies Company Profile

Lion Biotechnologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma.

5 Day Chart for NASDAQ:LBIO

Receive News & Stock Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related stocks with our FREE daily email newsletter.